Physician profile
Thomas L Young
NPI 1053493791
$20,272.37
in general payments reported to CMS, 2019-2025
33 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,928 · 2020: $6,705 · 2021: $164 · 2022: $850 · 2023: $1,202 · 2024: $1,395 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.32 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,054.74 | 2019-2020 | |
| Abbvie INC. | $2,405.75 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.79 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $325.34 | 2022-2025 | Ibsrela |
| Celgene Corporation | $255.96 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $239.57 | 2022-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $184.72 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $116.98 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $77.11 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $74.15 | 2022-2024 | Dificid |
| Janssen Biotech, INC. | $72.39 | 2022-2023 | Stelara, Simponi, Remicade |
| Aimmune Therapeutics, INC. | $71.77 | 2024-2025 | Zenpep |
| Medtronic, INC. | $69.04 | 2023 | Gi Genius, Prodigi |
| Celltrion USA INC. | $68.53 | 2023-2025 | Vegzelma, Yuflyma |
| Pfizer INC. | $61.37 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $58.98 | 2022-2024 | Ocaliva |
| Daiichi Sankyo INC. | $56.95 | 2022-2025 | Injectafer |
| Lilly USA, LLC | $54.84 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $51.45 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $36.92 | 2022 | |
| Organon LLC | $36.26 | 2022-2025 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $29.11 | 2022 | |
| Qol Medical, LLC | $27.34 | 2025 | Sucraid |
| Intra-Sana Laboratories | $26.47 | 2022 | |
| Mauna Kea Technologies, INC. | $23.95 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $23.71 | 2023 | Prehevbrio |
| Ferring Pharmaceuticals INC. | $22.08 | 2023 | Rebyota |
| Endogastric Solutions, INC | $21.22 | 2023 | Esophyx |
| Amgen INC. | $20.10 | 2023 | Avsola, Amjevita |
| Olympus America INC. | $18.49 | 2022 | |
| Boston Scientific Corporation | $16.93 | 2019 | |
| Axonics, INC. | $14.65 | 2024 | Axonics |
| Genzyme Corporation | $13.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.